A new website allows 340B Drug Pricing Program participants to determine the maximum drug companies can charge them for medications sold under the program. The website comes as a result of a recent lawsuit filed against the Health Resources and Services Administration by the American Hospital Association, which sought to force implementation of a final rule impacting drug ceiling prices and civil monetary penalties for manufacturers.
This item appears in
CMS Issues Initial Inflation Reduction Act Rebate Guidance for Part B DrugsCHA NewsDetails
340B Case Remanded to HHS to Determine Underpayment RemedyCHA NewsDetails
Court Rules HHS Must Restore Full 340B Payments to Hospitals for Rest of 2022CHA NewsDetails